Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Amortization of Deferred Charges: 2016-2025

Historic Amortization of Deferred Charges for Aytu Biopharma (AYTU) over the last 7 years, with Jun 2025 value amounting to $108,000.

  • Aytu Biopharma's Amortization of Deferred Charges rose 7.41% to $29,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $110,000, marking a year-over-year decrease of 76.89%. This contributed to the annual value of $108,000 for FY2025, which is 81.91% down from last year.
  • Aytu Biopharma's Amortization of Deferred Charges amounted to $108,000 in FY2025, which was down 81.91% from $597,000 recorded in FY2024.
  • Aytu Biopharma's Amortization of Deferred Charges' 5-year high stood at $597,000 during FY2024, with a 5-year trough of -$126,000 in FY2022.
  • Over the past 3 years, Aytu Biopharma's median Amortization of Deferred Charges value was $559,000 (recorded in 2023), while the average stood at $421,333.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first slumped by 186.36% in 2022, then surged by 543.65% in 2023.
  • Aytu Biopharma's Amortization of Deferred Charges (Yearly) stood at -$44,000 in 2021, then crashed by 186.36% to -$126,000 in 2022, then skyrocketed by 543.65% to $559,000 in 2023, then increased by 6.80% to $597,000 in 2024, then crashed by 81.91% to $108,000 in 2025.